The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM). Investigators have identified a biomarker associated with poor outcomes in multiple myeloma (MM) that ...

Triple-negative breast cancer (TNBC), particularly the luminal androgen receptor (LAR) subtype, presents significant ...

The Clinical Implications of Basic Research series has focused on highlighting laboratory research that could lead to advances in clinical therapeutics. However, the path between the laboratory and ...

In this study, we describe how flotillin-1 and -2 contribute to the stabilization of ErbB2 at the cell surface, and we show that ErbB2 is internalized and degraded by a GA-independent mechanism upon ...

"This study raises important questions deserving further consideration—notably how the location of the mutation in the HER2 protein and co-occurring mutations may impact the efficacy of HER2-targeting ...

Higher TIL levels in ERBB2-positive breast cancer correlate with improved DDFS and OS, suggesting a prognostic role. Patients with TILs greater than or equal to 20% may safely undergo shorter ...

Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer. Each 5% increase in TILs was ...

While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the ...

"Triple-negative breast cancer (TNBC), although clinically considered a single subtype, has multiple recognized molecular subtypes that could lead to differing outcomes. Currently, we treat all ...

Early assessment of treatment effect in advanced lung adenocarcinoma via longitudinal ctDNA analysis. Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker ...

Researchers conducted a retrospective cross-sectional analysis of patients diagnosed with de novo metastatic breast cancer to evaluate presentation and treatment differences across three main subtypes ...